223 related articles for article (PubMed ID: 18842592)
1. APOBEC3G subunits self-associate via the C-terminal deaminase domain.
Bennett RP; Salter JD; Liu X; Wedekind JE; Smith HC
J Biol Chem; 2008 Nov; 283(48):33329-36. PubMed ID: 18842592
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of the two cytidine deaminase domains in APOBEC3G.
Li X; Ma J; Zhang Q; Zhou J; Yin X; Zhai C; You X; Yu L; Guo F; Zhao L; Li Z; Zeng Y; Cen S
Virology; 2011 Jun; 414(2):130-6. PubMed ID: 21489586
[TBL] [Abstract][Full Text] [Related]
3. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.
Miller JH; Presnyak V; Smith HC
Retrovirology; 2007 Nov; 4():81. PubMed ID: 18036235
[TBL] [Abstract][Full Text] [Related]
4. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.
Zhang L; Saadatmand J; Li X; Guo F; Niu M; Jiang J; Kleiman L; Cen S
Virology; 2008 Jan; 370(1):113-21. PubMed ID: 17916373
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.
Bennett RP; Presnyak V; Wedekind JE; Smith HC
J Biol Chem; 2008 Mar; 283(12):7320-7. PubMed ID: 18165230
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.
Batisse J; Guerrero SX; Bernacchi S; Richert L; Godet J; Goldschmidt V; Mély Y; Marquet R; de Rocquigny H; Paillart JC
J Virol; 2013 Jun; 87(11):6492-506. PubMed ID: 23576497
[TBL] [Abstract][Full Text] [Related]
8. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
[TBL] [Abstract][Full Text] [Related]
9. Random mutagenesis MAPPIT analysis identifies binding sites for Vif and Gag in both cytidine deaminase domains of Apobec3G.
Uyttendaele I; Lavens D; Catteeuw D; Lemmens I; Bovijn C; Tavernier J; Peelman F
PLoS One; 2012; 7(9):e44143. PubMed ID: 22970171
[TBL] [Abstract][Full Text] [Related]
10. Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis.
Lavens D; Peelman F; Van der Heyden J; Uyttendaele I; Catteeuw D; Verhee A; Van Schoubroeck B; Kurth J; Hallenberger S; Clayton R; Tavernier J
Nucleic Acids Res; 2010 Apr; 38(6):1902-12. PubMed ID: 20015971
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
12. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G.
Cen S; Peng ZG; Li XY; Li ZR; Ma J; Wang YM; Fan B; You XF; Wang YP; Liu F; Shao RG; Zhao LX; Yu L; Jiang JD
J Biol Chem; 2010 May; 285(22):16546-52. PubMed ID: 20363737
[TBL] [Abstract][Full Text] [Related]
13. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G.
Furukawa A; Nagata T; Matsugami A; Habu Y; Sugiyama R; Hayashi F; Kobayashi N; Yokoyama S; Takaku H; Katahira M
EMBO J; 2009 Feb; 28(4):440-51. PubMed ID: 19153609
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.
Armitage AE; Deforche K; Chang CH; Wee E; Kramer B; Welch JJ; Gerstoft J; Fugger L; McMichael A; Rambaut A; Iversen AK
PLoS Genet; 2012; 8(3):e1002550. PubMed ID: 22457633
[TBL] [Abstract][Full Text] [Related]
15. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Wang X; York IA; Zheng YH
J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
[TBL] [Abstract][Full Text] [Related]
16. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
[TBL] [Abstract][Full Text] [Related]
17. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
18. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.
Iwabu Y; Kinomoto M; Tatsumi M; Fujita H; Shimura M; Tanaka Y; Ishizaka Y; Nolan D; Mallal S; Sata T; Tokunaga K
J Biol Chem; 2010 Nov; 285(46):35350-8. PubMed ID: 20833716
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.
Iwatani Y; Chan DS; Liu L; Yoshii H; Shibata J; Yamamoto N; Levin JG; Gronenborn AM; Sugiura W
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19539-44. PubMed ID: 19887642
[TBL] [Abstract][Full Text] [Related]
20. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]